Published in Cytotherapy on February 04, 2013
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness. Hum Gene Ther Methods (2014) 0.87
Chimeric Antigen Receptor T Cell Therapy in Hematology. Turk J Haematol (2015) 0.75
Remarkable stability of clinical grade reagents for gene-engineered T-lymphocyte production. Cytotherapy (2013) 0.75
Overriding of drug safety alerts in computerized physician order entry. J Am Med Inform Assoc (2005) 8.87
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Turning off frequently overridden drug alerts: limited opportunities for doing it safely. J Am Med Inform Assoc (2008) 2.31
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood (2010) 2.31
Cells meeting our immunophenotypic criteria of endothelial cells are large platelets. Cytometry B Clin Cytom (2007) 2.24
Drug safety alert generation and overriding in a large Dutch university medical centre. Pharmacoepidemiol Drug Saf (2009) 2.08
Dose selection in phase I studies: why we should always go for the top. J Clin Oncol (2008) 2.08
Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev (2009) 2.00
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother (2007) 1.86
Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension (2010) 1.79
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis (2008) 1.75
Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat (2008) 1.74
mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res (2011) 1.66
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res (2008) 1.61
Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res (2011) 1.58
Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat (2010) 1.52
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol (2008) 1.47
Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics (2008) 1.44
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol (2003) 1.41
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy (2011) 1.29
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol (2011) 1.28
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol (2013) 1.28
External quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom (2010) 1.24
MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.23
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol (2006) 1.21
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist (2010) 1.20
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Res Treat (2011) 1.19
KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer (2013) 1.16
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res (2009) 1.16
Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J Immunol (2007) 1.15
Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer. J Immunol (2008) 1.15
Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat (2010) 1.14
The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eur J Cancer (2008) 1.13
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist (2007) 1.12
Functionality test for drug safety alerting in computerized physician order entry systems. Int J Med Inform (2010) 1.11
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors. Cancer Res (2009) 1.10
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab (2011) 1.08
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat (2013) 1.08
T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med (2010) 1.07
Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy. Cytometry A (2008) 1.04
Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn (2011) 1.04
Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol (2003) 1.04
Understanding handling of drug safety alerts: a simulation study. Int J Med Inform (2010) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol Immunother (2010) 1.03
The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension (2011) 1.01
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. J Immunol (2005) 1.01
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther (2010) 0.99
Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol (2006) 0.99
MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer (2014) 0.98
Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res (2013) 0.97
The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother (2003) 0.96
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol (2012) 0.95
Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther (2002) 0.94
Circulating tumor cells and sample size: the more, the better. J Clin Oncol (2010) 0.94
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol (2012) 0.94
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer. Breast Cancer Res Treat (2008) 0.94
Time-dependent drug-drug interaction alerts in care provider order entry: software may inhibit medication error reductions. J Am Med Inform Assoc (2009) 0.94
Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension (2011) 0.94
Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? Oncologist (2013) 0.93
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics (2011) 0.93
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol (2008) 0.93
Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. Anticancer Drugs (2008) 0.92
Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol (2012) 0.92
MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs. J Immunol (2010) 0.92
Clinical value of circulating endothelial cell detection in oncology. Drug Discov Today (2012) 0.92
Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal (2009) 0.91
Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia? Blood Cells Mol Dis (2009) 0.90
How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharm Pract (Granada) (2012) 0.90
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens (2009) 0.89
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10. J Immunol (2006) 0.89
CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett (2011) 0.88
Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics (2014) 0.88
Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study. Cancer (2012) 0.88
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87